Clinical Cancer Research Targets Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blanc-Brude, O. P.
Right arrow Articles by Altieri, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blanc-Brude, O. P.
Right arrow Articles by Altieri, D. C.
Clinical Cancer Research Vol. 9, 2683-2692, July 2003
© 2003 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Therapeutic Targeting of the Survivin Pathway in Cancer

Initiation of Mitochondrial Apoptosis and Suppression of Tumor-associated Angiogenesis1

Olivier P. Blanc-Brude2, Mehdi Mesri3, Nathan R. Wall, Janet Plescia, Takehiko Dohi and Dario C. Altieri4

Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts 01605

Purpose: Molecular antagonists of the inhibitor of apoptosis protein survivin have shown promise as novel anticancer strategies for triggering tumor cell apoptosis, dysregulating mitotic progression, and inhibiting tumor growth in preclinical models. However, how survivin couples to the cell death machinery has remained elusive, and the relevant cellular targets of survivin antagonists have not been completely elucidated.

Experimental Design: Human umbilical vein and dermal microvascular endothelial cells were infected with replication-deficient adenoviruses encoding survivin (pAd-Survivin), green fluorescent protein (pAd-GFP), or a phosphorylation-defective survivin Thr34->Ala (pAd-T34A) dominant negative mutant. The effect of wild-type or mutant survivin was investigated on capillary network stability, endothelial cell viability, and caspase activation in vitro and on kinetics of tumor growth and development of angiogenesis in a breast cancer xenograft model in vivo. The cell death pathway initiated by survivin targeting was mapped with respect to cytochrome c release, changes in mitochondrial transmembrane potential, and apoptosome requirements using mouse embryonic fibroblasts deficient in Apaf-1 or caspase-9.

Results: Adenoviral transduction of endothelial cells with pAd-Survivin inhibited growth factor deprivation- or ceramide-induced apoptosis, reduced caspase-3 and -7 generation, and stabilized three-dimensional capillary networks in vitro. Conversely, expression of pAd-T34A caused apoptosis in umbilical vein and dermal microvascular endothelial cells and resulted in caspase-3 activity. Cell death induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis with release of cytochrome c and loss of mitochondrial transmembrane potential and was suppressed in Apaf-1 or caspase-9 knockout mouse embryonic fibroblasts. When injected in human breast cancer xenografts, pAd-T34A inhibited growth of established tumors and triggered tumor cell apoptosis in vivo. This was associated with a ~60% reduction in tumor-derived blood vessels by quantitative morphometry of CD31-stained tumor areas, and appearance of endothelial cell apoptosis by internucleosomal DNA fragmentation in vivo.

Conclusions: Survivin functions as a novel upstream regulator of mitochondrial-dependent apoptosis, and molecular targeting of this pathway results in anticancer activity via a dual mechanism of induction of tumor cell apoptosis and suppression of angiogenesis.




This article has been cited by other articles:


Home page
JCOHome page
A. W. Tolcher, A. Mita, L. D. Lewis, C. R. Garrett, E. Till, A. I. Daud, A. Patnaik, K. Papadopoulos, C. Takimoto, P. Bartels, et al.
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
J. Clin. Oncol., November 10, 2008; 26(32): 5198 - 5203.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. J. Virrey, S. Guan, W. Li, A. H. Schonthal, T. C. Chen, and F. M. Hofman
Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells
Am. J. Pathol., August 1, 2008; 173(2): 575 - 585.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. H. Oh, Q. Jin, E. S. Kim, F. R. Khuri, and H.-Y. Lee
Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin-Mediated Increases in Survivin Expression
Clin. Cancer Res., March 1, 2008; 14(5): 1581 - 1589.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. G. Leung, Y. Xu, B. Mularski, H. Liu, S. Gurbuxani, and J. D. Crispino
Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells
J. Exp. Med., July 9, 2007; 204(7): 1603 - 1611.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhang, T. S. Park, and J. M. Gidday
Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2573 - H2581.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
O. P. Blanc-Brude, E. Teissier, Y. Castier, G. Leseche, A.-P. Bijnens, M. Daemen, B. Staels, Z. Mallat, and A. Tedgui
IAP Survivin Regulates Atherosclerotic Macrophage Survival
Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 901 - 907.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. K. Knauer, O. H. Kramer, T. Knosel, K. Engels, F. Rodel, A. F. Kovacs, W. Dietmaier, L. Klein-Hitpass, N. Habtemichael, A. Schweitzer, et al.
Nuclear export is essential for the tumor-promoting activity of survivin
FASEB J, January 1, 2007; 21(1): 207 - 216.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
J. Immunol., December 15, 2006; 177(12): 8410 - 8421.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Fukuda and L. M. Pelus
Survivin, a cancer target with an emerging role in normal adult tissues
Mol. Cancer Ther., May 1, 2006; 5(5): 1087 - 1098.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
B. M. Ryan, G. E. Konecny, S. Kahlert, H.-J. Wang, M. Untch, G. Meng, M. D. Pegram, K. C. Podratz, J. Crown, D. J. Slamon, et al.
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
Ann. Onc., April 1, 2006; 17(4): 597 - 604.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. C. Altieri
Targeted therapy by disabling crossroad signaling networks: the survivin paradigm.
Mol. Cancer Ther., March 1, 2006; 5(3): 478 - 482.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
J. Rosa, P. Canovas, A. Islam, D. C. Altieri, and S. J. Doxsey
Survivin Modulates Microtubule Dynamics and Nucleation throughout the Cell Cycle
Mol. Biol. Cell, March 1, 2006; 17(3): 1483 - 1493.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura
Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo
J. Med. Genet., February 1, 2006; 43(2): 119 - 128.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Xiang, N. Mizutani, Y. Luo, C. Chiodoni, H. Zhou, M. Mizutani, Y. Ba, J. C. Becker, and R. A. Reisfeld
A DNA Vaccine Targeting Survivin Combines Apoptosis with Suppression of Angiogenesis in Lung Tumor Eradication
Cancer Res., January 15, 2005; 65(2): 553 - 561.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
W. Zhang, A. N. Hanks, K. Boucher, S. R. Florell, S. M. Allen, A. Alexander, D. E. Brash, and D. Grossman
UVB-induced apoptosis drives clonal expansion during skin tumor development
Carcinogenesis, January 1, 2005; 26(1): 249 - 257.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Krysan, H. Dalwadi, S. Sharma, M. Pold, and S. Dubinett
Cyclooxygenase 2-Dependent Expression of Survivin Is Critical for Apoptosis Resistance in Non-Small Cell Lung Cancer
Cancer Res., September 15, 2004; 64(18): 6359 - 6362.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Dohi, K. Okada, F. Xia, C. E. Wilford, T. Samuel, K. Welsh, H. Marusawa, H. Zou, R. Armstrong, S.-i. Matsuzawa, et al.
An IAP-IAP Complex Inhibits Apoptosis
J. Biol. Chem., August 13, 2004; 279(33): 34087 - 34090.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Beltrami, J. Plescia, J. C. Wilkinson, C. S. Duckett, and D. C. Altieri
Acute Ablation of Survivin Uncovers p53-dependent Mitotic Checkpoint Functions and Control of Mitochondrial Apoptosis
J. Biol. Chem., January 16, 2004; 279(3): 2077 - 2084.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
P. Fortugno, E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P. C. Marchisio, W. C. Sessa, and D. C. Altieri
Regulation of survivin function by Hsp90
PNAS, November 25, 2003; 100(24): 13791 - 13796.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.